Acyclovir is well tolerated, but renal adjustments and allergy screening are important before starting therapy in children.
Absolute contraindication is hypersensitivity to acyclovir or valacyclovir. Relative precautions include renal impairment, dehydration, concomitant nephrotoxic drugs, and underlying neurologic disease that could predispose to neurotoxicity.
Risk of rapid-onset urticaria, angioedema, or anaphylaxis; rechallenge not recommended outside desensitization programs.
Crystalluria and acute kidney injury can develop rapidly when serum levels accumulate.
If used, monitor: Check creatinine, adjust dose/interval, maintain ≥1 mL/kg/hr urine output, hold concurrently nephrotoxic agents when feasible.
High serum levels can precipitate encephalopathy, hallucinations, or seizures.
If used, monitor: Lower doses, monitor mental status daily, and pause therapy for unexplained neurologic changes.
Specific drugs: Probenecid
Effect: Increased risk of nephrotoxicity and neurotoxicity.
How it happens: Inhibits renal tubular secretion of acyclovir, raising serum concentrations.
Management: Avoid combination when possible; otherwise reduce acyclovir dose and monitor creatinine q48h.
Specific drugs: Lithium
Effect: Lithium toxicity (tremor, ataxia, vomiting).
How it happens: Competition for renal excretion increases lithium levels.
Management: Check lithium levels after 2–3 days of concomitant therapy; adjust lithium dose or choose alternative antiviral.
Specific drugs: Calcineurin inhibitors (tacrolimus, cyclosporine)
Effect: Rapid rise in creatinine and electrolyte disturbances.
How it happens: Additive nephrotoxicity with reduced renal perfusion.
Management: Ensure IV hydration, stagger dosing, monitor kidney function twice weekly.
Specific drugs: NSAIDs at high doses
Effect: Acute kidney injury in dehydrated adolescents.
How it happens: Decreased renal blood flow compounds crystalluria risk.
Management: Limit NSAID use; use acetaminophen for pain/fever when possible.